Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-B9) – Biotin

SARS-CoV-2 Nucleocapsid (N) Protein

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Ships Overnight on Blue Ice

Anti-SARS-CoV-2 Nucleocapsid, clone NP1-B9, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Futhermore, it is reported to bind to the oligomerization domain of the N protein.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus belonging to the Coronaviridae family¹. The SARS-CoV-2 genome encodes four essential proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins². SARS-CoV-2 shares 79.6% identity with the original SARS-CoV². The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in a couple of primary functions, including RNA binding and self-oligomerization^3,4. This results in binding to and packaging of the viral RNA genome into a helical ribonucleoprotein⁵. The N protein is involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways^6,7. The N protein is a suitable candidate for vaccine development and diagnostic assays⁸ for several reasons. It is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein⁹. Furthermore, antibodies^9,10 and memory T cells^11,12 targeting the N protein are identified in the sera of convalescent COVID-19 patients, demonstrating it as immunogenic. The N protein also suppresses antiviral RNAi, evading the innate immune system¹³, suggesting its potential value as a targeted therapeutic.

The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
8. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
9. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
10. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
11. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.
12. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.